| Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice. | |
| | |
MedLine Citation:
|
PMID: 20504222 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Sunitinib is a reference standard of care for the treatment of metastatic renal cell carcinoma (mRCC). While the tolerability of sunitinib is consistent across clinical studies, the impact of tolerability on clinical benefit necessitates effective therapy management, focusing on optimization of dosing, treatment duration, and management of adverse events. Managing individual tolerability concerns in clinical practice should include patient education and practical management strategies. We review the sunitinib tolerability profile in mRCC and describe practical strategies to manage adverse events in order to maximize clinical benefit. These strategies may allow long-term sunitinib treatment, thereby optimizing the available clinical efficacy. |
| | |
Authors:
|
Manuela Schmidinger; Dirk Arnold; Cezary Szczylik; John Wagstaff; Alain Ravaud |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Cancer investigation Volume: 28 ISSN: 1532-4192 ISO Abbreviation: Cancer Invest. Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-09-15 Completed Date: 2010-10-27 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8307154 Medline TA: Cancer Invest Country: England |
Other Details:
|
Languages: eng Pagination: 856-64 Citation Subset: IM |
Affiliation:
|
University of Vienna, Vienna, Austria. manuela.schmidinger@meduniwien.ac.at |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angiogenesis Inhibitors
/
adverse effects,
therapeutic use Antineoplastic Agents / adverse effects, therapeutic use* Asthenia / chemically induced, prevention & control Carcinoma, Renal Cell / drug therapy*, pathology Clinical Trials as Topic Dose-Response Relationship, Drug Drug Tolerance Fatigue / chemically induced, prevention & control Humans Indoles / adverse effects, therapeutic use* Kidney Neoplasms / drug therapy*, pathology Medical History Taking Neoplasm Metastasis / drug therapy Proportional Hazards Models Pyrroles / adverse effects, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Angiogenesis Inhibitors; 0/Antineoplastic Agents; 0/Indoles; 0/Pyrroles; 0/sunitinib |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Should cause of death from the death certificate be used to examine cancer-specific survival? A stud...
Next Document: High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcom...